Abstract
Heart failure is a common condition, associated with both poor prognosis and poor quality of life. In contrast to all other cardiovascular diseases, the prevalence of heart failure is increasing in the western world, and is likely to continue to do so as the population ages. In the UK, a significant proportion of patients with heart failure come from South Asian and African Caribbean ethnic groups. A large body of evidence exists that there may be epidemiological and pathophysiological differences between patients with heart failure from different ethnic groups. Treatments such as ACE inhibitors, which are now part of standard heart failure therapy, have an evidence base consisting of trials in patients of almost exclusively white ethnicity. Such treatments may not be equally effective in patients from other ethnic groups. This review will discuss the current evidence for heart failure management with respect to ethnicity, and consider the implications for future drug development and implications for antihypertensive therapy.
Keywords: heart failure, breast cancer, angiotensin converting enzyme (ace) inhibitors, hypertension, type II diabetes mellitus, coronary atherosclerosis
Current Pharmaceutical Design
Title: Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Volume: 10 Issue: 29
Author(s): Michael D. Sosin, Gurbir S. Bhatia, Gregory Y.H. Lip and Russell C. Davis
Affiliation:
Keywords: heart failure, breast cancer, angiotensin converting enzyme (ace) inhibitors, hypertension, type II diabetes mellitus, coronary atherosclerosis
Abstract: Heart failure is a common condition, associated with both poor prognosis and poor quality of life. In contrast to all other cardiovascular diseases, the prevalence of heart failure is increasing in the western world, and is likely to continue to do so as the population ages. In the UK, a significant proportion of patients with heart failure come from South Asian and African Caribbean ethnic groups. A large body of evidence exists that there may be epidemiological and pathophysiological differences between patients with heart failure from different ethnic groups. Treatments such as ACE inhibitors, which are now part of standard heart failure therapy, have an evidence base consisting of trials in patients of almost exclusively white ethnicity. Such treatments may not be equally effective in patients from other ethnic groups. This review will discuss the current evidence for heart failure management with respect to ethnicity, and consider the implications for future drug development and implications for antihypertensive therapy.
Export Options
About this article
Cite this article as:
Sosin D. Michael, Bhatia S. Gurbir, Lip Y.H. Gregory and Davis C. Russell, Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension, Current Pharmaceutical Design 2004; 10 (29) . https://dx.doi.org/10.2174/1381612043382783
DOI https://dx.doi.org/10.2174/1381612043382783 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycaemic Control: A Balancing Act or A Different Approach?
Current Diabetes Reviews The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science The Fetal Cardiac Function
Current Cardiology Reviews Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets New Insights on the Mode of Action of Microcystins in Animal Cells - A Review
Mini-Reviews in Medicinal Chemistry Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review
Current Vascular Pharmacology The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design The Immunologic Barriers to Replacing Damaged Organs
Current Immunology Reviews (Discontinued) Analytical Methods for the Determination of Anti-diuretic Peptides in Biological Samples: Challenges and Perspectives
Current Analytical Chemistry Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Hydrogen Sulphide in Heart and Systemic Circulation
Inflammation & Allergy - Drug Targets (Discontinued) Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Indolo[3,2-b]quinolines: Synthesis, Biological Evaluation and Structure Activity-Relationships
Mini-Reviews in Medicinal Chemistry The Critical Roles of HSC70 in Physiological and Pathological Processes
Current Pharmaceutical Design Patent Review
Combinatorial Chemistry & High Throughput Screening Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine